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Objective: To investigate blood pressure variability of Elder hyperten-
sives with type 2 diabetes and its relationship with cognition. Methods: 
A total of 143 elderly hypertensives were enrolled and divided into 
diabetic group (59 cases) and non-diabetic group (84 cases). The differ-
ence of general clinical characteristics, biochemical parameters, carotid 
ultrasound, a neuropsychological Scales and 24-hour ambulatory blood 
pressure (24hABPM) parameters between the two groups of subjects 
were compared. Then, the two groups (diabetic group and non-diabetic 
group) were further divided into (Mild cognitive dysfunction) subgroup 
(MMSE>26) and normal cognition subgroup (MMSE≤26), respectively. 
On the basis of MMSE scores, the difference of the parameters of ABPM 
between the two subgroups was analyzed. Results: Compared with the 
control group, 24hSBP, 24hPP, dSBP, dPP, nSBP, nPP, 24hSSD, dSSD, 
nSSD, 24hSCV, dSCV and nSCV were significantly higher in the diabetic 
group (p<0.05). However, cognition was lower in the diabetic group. No 
significant difference was found in the circadian pattern of blood pressure 
between the two groups. 24hSSD, dSSD, nSSD, 24hSCV, dSCV, nSCV 
were significantly higher in the MCI subgroup than normal cognition sub-
group in both diabetic and non-diabetic groups(p<0.05), and they were 
negatively associated with scores of MMSE, the correlation coefficient 
were -0.235, -0.246, -0.341, -0.158, -0.222, -0.238 (0.001≤P<0.05). Con-
clusion: The study showed that in the elderly with hypertension, the mean 
systolic blood pressure and blood pressure variability were both higher in 
the diabetic group, and the cognition was lower instead. Whether or not 
with diabetes, blood pressure variability was always higher in the MCI 
subgroup. Blood pressure variability increased in patients with diabetes, 
and was associated with cognitive decline.
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1. Introduction
With the changes in modern lifestyles, the prevalence 
of diseases such as diabetes and high blood pressure is 
increasing. The World Health Organization estimates that 
approximately 1.5 billion adults worldwide are affected 
by high blood pressure, which accounts for more than 
one-third of the adult population worldwide, and that the 
proportion increases with age. At present, the number of 
hypertension patients in China has exceeded 330 million, 
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with one in every three adults suffering from hyperten-
sion. The resulting heart disease and stroke can cause 
9.4 million deaths worldwide each year. According to 
the latest statistics from the International Diabetes Fed-
eration (IDF) in 2013, the global prevalence of diabetes 
in adults aged 20-79 is 8.3%, and the number of patients 
has reached 382 million [1]. In 2013, a total of 5.1 million 
people worldwide died of diabetes-related diseases, ac-
counting for 8.39% of all deaths. In China, the prevalence 
of diabetes has nearly doubled in the past decade. In 2010, 
the prevalence of adult diabetes in China was 9.7%. The 
total number of patients has exceeded 90 million. China 
has become the world's largest country with diabetes.
At the same time, with the improvement of material 
life and medical conditions and the extension of life ex-
pectancy, the aging of the population in modern society 
is accelerating, and the incidence of alzheimer's disease 
is also increasing year by year. According to statistics, 
there are currently 5 million Alzheimer's patients in Chi-
na, accounting for about 1/4 of the total number of cases 
in the world. The incidence rate of people over 55 years 
old is close to 3%, and the incidence rate of people over 
65 years old is more than 5% [2]. Following cardiovascular 
and cerebrovascular diseases and cancer, senile dementia 
has become a major disease threatening the health of the 
elderly. Because of the lack of interventions, the treatment 
of advanced alzheimer's disease is not effective. There-
fore, the early diagnosis and treatment of alzheimer's dis-
ease is particularly important.
Thus, in 1999, Petersen et al. proposed the concept of 
Mild cognitiveimpairment (MCI) [3]. MCI refers to the 
cognitive impairment state that cognitive function is lower 
than normal people of the same age and cultural back-
ground but does not reach the level of dementia, and their 
daily life is not affected. It is a clinically transitional state 
characterized by disease between normal aging and Alz-
heimer's disease (AD) or other early stages of dementia. 
Studies have shown that MCI has a large heterogeneity, 
and its annual conversion rate for dementia varies greatly. 
In 2008, Petersen [4] refined MCI into two types: amnestic 
(aMCI) and non-memory (nmMCI). Each category is di-
vided into single-domain and multi-domain. Among them, 
aMCI type is considered to have a high risk of developing 
into AD.
More and more evidences show that vascular factors 
play an important role in the development and progression 
of Alzheimer's disease. These cardiovascular risk factors 
can be used as a target therapy to reduce the incidence 
of cognitive dysfunction and dementia. Bell RD et al. [5] 
found in brain imaging studies of human and animal mod-
els that cerebral vascular dysfunction may precede cog-
nitive decline and neurodegenerative changes. Decreased 
cerebral blood flow can affect the synthesis of proteins 
needed for learning and memory, and may eventually 
lead to nerve damage and nerve cell death. Genome-wide 
association studies confirmed that the ApoEε4 allele is 
the strongest genetic risk factor for AD [6]. Studies have 
shown that carriers of the ApoE ε4 allele are predisposed 
to hypertension and coronary heart disease. This suggests 
that it is related to the development of cardiovascular dis-
ease and AD [7]. J zhu et al. found that MCI patients with 
intracranial artery stenosis are more likely to progress to 
AD dementia [8]. A study conducted by Zhou Huadong 
et al. in Daping Hospital of the Third Military Medical 
University on 837 MCI patients showed that vascular risk 
factors could increase the risk of AD dementia [9]. Ac-
tive intervention of VRF can improve the progression of 
MCI to AD dementia. The study found that patients with 
vascular risk factors had a higher risk of developing Alz-
heimer's disease than those without vascular risk factors. 
Controlling vascular risk factors can improve the progres-
sion of mild cognitive impairment to AD.
Hypertension causes the wall of cerebral arteries and 
arterioles to become thicker and harder, and the lumen to 
become smaller, which in turn reduces cerebral blood flow 
and leads to abnormal brain energy metabolism. In addi-
tion, the cerebral cortical arterial wall is glass-like, and the 
lumen becomes smaller, which constitutes a subcortical 
white matter with low perfusion. This impairs brain ener-
gy metabolism. The use of glucose in the brain decreased 
and local protein synthesis was abnormal. Neurotransmit-
ters become dysfunctional and cholinergic receptors are 
absent, which causes neuronal damage in the white matter 
and hippocampus and leads to cognitive dysfunction.
Blood pressure level fluctuates constantly under the 
influence of various physiological, pathological, envi-
ronmental and genetic factors. The degree of fluctuation 
of blood pressure over a certain period of time (includ-
ing physiological variation, pathological variation, and 
drug-induced variation) is called blood pressure variability 
(BPV). It has been generally believed that the mean blood 
pressure of hypertensive patients is closely related to the 
damage of target organs. At the same time, the average 
blood pressure is also an important parameter in the clin-
ical diagnosis and treatment of hypertension. Current ma-
jor clinical guidelines also support the idea that lowering 
average blood pressure can reduce target organ damage. 
However, with the development of dynamic blood pres-
sure monitoring technology, people's research on blood 
pressure fluctuations has gradually deepened. More and 
more clinical studies have shown that BPV is an effective 
predictor of target organ damage and is independent of 
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average blood pressure.
Recently, researchers at the Leiden University Med-
ical Center in the Netherlands, the University of Cork 
in Ireland and the University of Glasgow in the United 
Kingdom investigated the relationship between blood 
pressure variability (independent of blood pressure) and 
cognitive function in the elderly at high risk for cardiovas-
cular disease [10]. The results suggest that increased blood 
pressure variability is inversely associated with various 
cognitive function tests and is associated with a higher 
risk of stroke. This association was independent of a va-
riety of other cardiovascular risk factors, including blood 
pressure levels. The reasons are as follows: first, blood 
pressure variability and cognitive impairment may result 
from a common cause, that is, cardiovascular risk factors. 
Second, blood pressure variability may reflect long-term 
instability of blood pressure and blood flow regulation in 
the main organs of the body. Third, severe fluctuations in 
blood pressure in the brain may cause the brain to fail to 
receive adequate blood flow, leading to brain damage and 
cognitive dysfunction.
In recent years, studies have shown that long-term 
hyperglycemia in diabetes can cause vascular endothelial 
function and platelet agglutination dysfunction, resulting 
in lacunar cerebral infarction and cerebral thrombosis and 
other complications. Marioni et al. [11] showed that the in-
crease of plasma viscosity in patients with type 2 diabetes 
was positively correlated with the decline of cognitive 
function. At the same time, the blood-brain barrier integ-
rity is impaired, cerebral blood flow and cerebral vascular 
surface area are reduced, resulting in reduced transport of 
essential nutrients to nerve tissue, which in turn affects 
synaptic function. Abnormal glucose metabolism can lead 
to cardiovascular autonomic nervous system dysfunction 
in the body, aggravating essential hypertension and caus-
ing structural and functional abnormalities of the cardio-
vascular system. BPV reflects the effect of cardiovascular 
autonomic nerve on hemodynamics. At present, there have 
been many studies on cognitive function in patients with 
hypertension and type 2 diabetes. However, there are few 
studies on the effect of blood pressure variability of dia-
betes mellitus combined with hypertension on cognitive 
function.
In this study, the 24-hour dynamic blood pressure and 
neurocognitive scale of 59 patients with hypertension with 
type 2 diabetes and 84 patients with simple hypertension 
were measured respectively to study the correlation. The 
relationship between blood pressure variability and cog-
nitive function in elderly patients with hypertension and 
type 2 diabetes mellitus was investigated.
2. Materials and Methods
2.1 Research Object
(1) Cases Resource
A total of 143 patients with hypertension were admitted 
to the Geriatrics Department of the Sixth People's Hospi-
tal of Shanghai from August 2012 to December 2013.
(2) Case Grouping
These patients were divided into the elderly hyper-
tension group (diabetes group, 59 cases) and the elderly 
simple hypertension group (control group, 84 cases). Ac-
cording to the cognitive function, the diabetic group was 
divided into the subgroup with normal cognitive function 
of hypertension and diabetes mellitus (MMSE>26, 16 
cases) and the subgroup with mild cognitive impairment 
of diabetes mellitus (diabetes MCI subgroup, MMSE ≤26, 
43 cases). The control group was also divided into non-di-
abetic cognitive function subgroup (MMSE>26, 41 cases) 
and non-diabetic mild cognitive dysfunction subgroup 
(non-diabetic MCI subgroup, MMSE≤26, 43 cases) ac-
cording to cognitive function.
(3) Inclusion Criteria
"China Guidelines for the Prevention and Treatment of 
Hypertension 2010 Edition" [12] Diagnostic Criteria: Blood 
pressure was measured 3 times on different days without 
antihypertensive drugs. Patients with primary hyperten-
sion were diagnosed with systolic blood pressure ≥140 
mmHg and/or diastolic blood pressure ≥90 mmHg.
Diagnostic criteria for type 2 diabetes use the 2010 
edition of the Chinese Type 2 DM prevention guidelines 
diagnostic criteria [13]: Fasting blood glucose (FPG) ≥ 
7.0mmol / L or 2h after meal (2hPG) ≥ 11.1mmol / L, 
while eliminating secondary diabetes. Or the patient has 
been diagnosed with diabetes in the past. Although the 
blood glucose level has not reached the diagnostic criteria, 
the patients who have been treated with hypoglycemic.
The level of education is university and above.
(4) Exclusion Criteria
A. Patients with secondary hypertension caused by 
renal hypertension, neuroendocrine disorders, mechanical 
blockage of blood flow, and poor blood pressure control, 
systolic blood pressure > 180 mmHg and / or diastolic 
blood pressure > 110 mmHg;
B. Patients with severe heart and lung disease;
C. Patients with acute complications of diabetes such 
as tumors, infectious diseases, hypoglycemia coma, dia-
betic ketoacidosis, non-ketotic hyperosmolar coma;
D. Stroke, Parkinson's disease, brain trauma, persistent 
episodes of epilepsy, vitamin B12 deficiency, hypothy-
roidism, obstructive respiratory sleep apnea;
E. Depression patients with a score greater than 10 on 
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the geriatric depression scale;
F. Patients with impaired daily living ability who 
scored more than 20 on the daily living ability scale;
G. Patients taking drugs that improve cognitive func-
tion (cholinesterase inhibitors: including huperzine A, 
donepezil, rivastigmine tartaric acid, galantamine, etc.; 
excitatory amino acid receptor antagonist: Ebixa).
2.2 Research Method
The age, sex, smoking history, and antihypertensive med-
ication use of all subjects were recorded. In the morning, 
the patient's blood is drawn to measure fasting plasma 
glucose (FPG). Based on 24h ambulatory blood pressure 
monitoring (24hABPM) and neuropsychological scale 
measurement (including MMSE, GDS, ADL scale), 2-hour 
postprandial blood glucose (P2hPG), hemoglobin A1C 
(HbA1C), alanine transaminase (ALT), serum creatinine 
(Scr), thyroid function (FT3, FT4, TSH), vitamin B12 (Vit 
B12), cholesterol (TC), triglyceride (TG), high-density 
lipoprotein (HDL), low density lipoprotein (LDL) were 
detected.
(1) Assessment of smoking history: According to the 
World Health Organization smoking survey standards, a 
minimum of one cigarette per day before the hospitaliza-
tion, continuous smoking lasts for more than one year, or 
long-term smoking but smoking cessation for less than 
half a year is positive for smoking.
(2) Blood biochemical testing: ALT, Scr, TC, TG, 
HDL-C, LDL-C, FPG, and P2hPG were detected by an 
automated biochemical analyzer (U.S., Backman LX20). 
The FT3, FT4, and TSH were tested by the Roche Cobas 
6000. The VitB12 is tested by Siemens ADVIA centaur 
XP. HbA1C is detected by the UK's DREW-DS5 high 
pressure liquid phase analyzer.
(3) Ambulatory blood pressure monitoring: Noninva-
sive portable cuff blood pressure monitor (SPACELABS 
Healthcare 90217) was used to measure the left upper 
limb artery pressure for 24 hours. The blood pressure is 
measured automatically at intervals of 30 minutes during 
the day and 1 hour during the night, and the patient's ac-
tivity is not restricted during the monitoring period. 24 
hours later, the data were analyzed: 8:00~23:00 is blood 
pressure of the day, and 23:00~8:00 is the blood pres-
sure at night. The computer automatically analyzed the 
mean value of systolic and diastolic blood pressure, pulse 
pressure, standard deviation, and 24-hour blood pressure 
circadian rhythm in patients with 24-hour blood pressure 
effective reading >80% of each time period (24 hours, 
day, night).
(4) Observation indicators: Daytime systolic pressure 
standard deviation (dSSD), daytime diastolic pressure 
standard deviation (dDSD), nighttime systolic pressure 
standard deviation (nSSD), nighttime diastolic pressure 
standard deviation (nDSD), and 24-hour systolic blood 
pressure, diastolic blood pressure weighted standard devi-
ation (24hSSD, 24hDSD). The calculation formula is: 24-
hour systolic blood pressure weighted standard deviation 
(24hSSD) = [(dSSD×14)+ (nSSD×6)]/20, 24 hours dia-
stolic pressure plus weight standard deviation (24hDSD) 
= [(dDSD×14) +(nDSD×6)]/20. According to the blood 
pressure coefficient of variation CV = SD / blood pressure 
mean × 100%, the 24h systolic blood pressure variation 
coefficient (24hSCV), 24h diastolic blood pressure vari-
ation coefficient (24hDCV), daytime systolic blood pres-
sure variation coefficient (dSCV), daytime diastolic blood 
pressure variation coefficient (dDCV), nighttime systolic 
blood pressure variation coefficient (nSCV), and night-
time diastolic blood pressure variation coefficient (nDCV) 
were calculated respectively.
(5) Minimum Mental State Examination (MMSE):
The Minimum Mental State Examination (MMSE) was 
compiled by Folstein in 1975. It is one of the most widely 
used screening tools for cognitive impairment. The scale 
assessment items include: time orientation, location ori-
entation, language immediate memory, attention and cal-
culation, short-term memory, naming, language retelling 
and understanding and expression, spatial structure. The 
total score is 30 points. The lower the score, the worse the 
cognitive assessment. Subjects with a college degree or 
above were included, and their MMSE>26 was classified 
as normal cognition, while 26 was defined as MCI.
(6) The Geriatric Depression Scale (GDS):
The Geriatric Depression Scale (GDS) was created by 
Brink et al. (1982). This is a depression screening form 
for the elderly. Brink et al. (1982), Yesavage et al. (1983), 
Hyer and Blount (1984) tested GDS, respectively. The re-
sults show that GDS has good reliability and validity, and 
has a high correlation with commonly used depression 
scales such as SDS, HRSD and BDI.
(7) Activities of Daily Living (ADL):
By asking the patients or their families for scores, the 
medical staff can assess the patients' daily life functions. 
The assessment program includes 20 daily living abilities. 
In each category, 1 = can do it oneself, 2 = have some dif-
ficulty, 3 = need help, and 4 = can't do it at all. The total 
score of 20 is normal. The total score of >26 or more than 
two functional loss is considered deficiency in daily living 
ability.
2.3 Statistical Treatment
SPSS 17.0 statistical software was used to process the 
data. Measurement data are expressed as (±s). The nor-
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mality test is performed on the measurement data. The test 
results show that the measurement data conforms to the 
normal distribution (P>0.05), and the homogeneity of the 
posterior difference is tested. P>0.05 indicated homoge-
neity of variance, and t test was used. P<0.05 means het-
erogeneity of variance, and t' test is adopted. Qualitative 
data are described by rate (or constituent ratio). The χ2 
test was used to compare the rate (or composition ratio) of 
each group. Multivariate correlations were analyzed using 
Pearson correlation. P < 0.05 was considered statistically 
significant.
3. Results
3.1 General Clinical Data
143 patients were enrolled. There were 59 patients in the 
diabetic group, including 45 males (84.33±4.39 years old) 
and 14 females (83.86±3.95 years old). There were 84 pa-
tients in the control group, including 64 males (83.55±4.69 
years old) and 20 females (84.65±5.56 years old). The age, 
sex, smoking history, antihypertensive medication type, 
ALT, Scr, TC, TG, HDL-C, LDL-C, Vit B 12, folic acid, 
FT3, FT4, TSH were compared between the two groups. 
The difference was not statistically significant (P>0.05). 
The FPG, P2hPG and HbA1C in the diabetic group were 
compared with the control group, and the difference was 
statistically significant (P<0.05). The baseline balance of 
the two groups was consistent and the comparability was 
good, as shown in Tables 1 and 2.
Table 1. Comparison of general conditions between dia-
betic group and control group
Item Diabetes group n=59
Control group 
n=84 t or χ
2 P
Age 84.22±4.58 83.81±4.90 0.507 0.613
Gender (male/
female) 45/14 64/20 0.000 0.991
Smoking histo-
ry 6.06±0.76 6.13±0.84 1.811 0.178
ALT(u/l) 37.43±25.87 40.56±31.23 0.632 0.528
Scr (mmol/l) 81.40±23.22 79.40±30.57 0.423 0.672
TC (mmol/l) 4.20±0.98 4.13±0.94 0.430 0.668
TG (mmol/l) 1.34±1.07 1.21±0.66 0.115 0.391
HDL (mmol/l) 1.44±0.85 1.70±0.98 0.131 0.100
LDL (mmol/l) 2.27±0.86 2.06±0.91 0.999 0.168
Vit B12 (ng/L) 878.97±232.56 905.43±214.35 0.701 0.484
Folic acid (ug/l) 12.12±3.45 13.06±3.62 1.558 0.121
FT3 (pmol/L) 4.14±1.15 4.03±0.96 0.621 0.535
FT4 (pmol/L) 18.69±4.56 19.04±3.98 0.487 0.626
TSH (mIU/l) 3.88±0.98 3.96±0.87 0.513 0.608
FPG (mmol/l) 5.99±1.70 5.48±0.87 0.000 0.041 *
P2hPG(mmol/l) 9.18±2.88 7.70±2.18 0.005 0.001*
HbA1C 6.86±1.19 5.99±0.87 0.052 0.000 **
Note: * indicates 0.001 < P < 0.05 compared with the control group. ** 
indicates P < 0.001 compared with the control group.
Table 2. Comparison of antihypertensive drugs between 
diabetic group and control group
Antihypertensive drugs Diabetes group n=59
Control group 
n=84 χ
2 P
Long-acting CCB 34 52
ARB 28 40
ACEI 13 19 0.364
β receptor blockers 8 14 0.784
Diuretic 8 12
Others 2 3
Note: Long-acting CCB: long-acting calcium antagonist; ARB: angio-
tensin receptor antagonist; ACEI: angiotensin-enzyme conversion agent
3.2 Comparison of Mean Blood Pressure Between 
Diabetic Group and Control Group
The levels of 24hSBP, 24hPP, dSBP, dPP, nSBP and nPP 
in the diabetic group were higher than those in the con-
trol group. The differences were statistically significant 
(P<0.05). The comparison of mean blood pressure be-
tween the diabetic group and the control group is shown 
in Table 3.
Table 3. The comparison of mean blood pressure between 
the diabetic group and the control group
Observation 
index
Diabetes group 
n=59
Control group 
n=84 t P
24hSB-
P(mmHg) 126.97±18.70 119.82±15.35 2.501 0.014
 *
24hDB-
P(mmHg) 61.79±10.05 61.74±8.25 0.235 0.972
24hPP(mmHg) 65.19±14.52 57.82±12.18 0.228 0.001 *
dSBP(mmHg) 127±18.89 119.90±14.72 0.019 0.017 *
dDBP(mmHg) 61.87±10.25 62.27±8.56 0.306 0.800
dPP(mmHg) 65.12±14.73 57.66±12.03 0.235 0.001 *
nSBP(mmHg) 128.66±21.99 119.60±20.47 0.987 0.045 *
nDBP(mmHg) 61.29±11.39 60.42±11.90 1.000 0.663
nPP(mmHg) 65.37±16.46 59.17±16.98 0.739 0.031 *
Note: * indicates 0.001 < P < 0.05 compared with the control group.
3.3 Comparison of Blood Pressure Variability be-
tween Diabetic Group and Control Group
The results of 24hSSD, dSSD, nSSD, 24hSCV, dSCV, and 
nSCV were compared between the two groups, and the 
diabetic group was higher than the control group (p<0.05). 
The comparison of blood pressure variability between di-
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abetic group and control group is shown in Table 4.
Table 4. The comparison of blood pressure variability 
between diabetic group and control group
Observation 
index
Diabetes 
group n=59
Control group 
n=84 t P
24hSSD 14.03±5.17 11.31±2.83 0.290 0.000 **
24hDSD 7.59±1.96 7.96±2.05 0.849 0.283
dSSD 13.60±3.67 11.33±2.94 0.095 0.000 **
dDSD 7.56±2.24 7.89±2.35 0.811 0.409
nSSD 13.34±3.47 11.27±3.95 0.154 0.001 *
nDSD 7.66±2.58 8.13±3.00 0.234 0.328
24hSCV 11.27±4.61 9.51±2.41 0.024 0.009 *
24hDCV 12.50±3.47 13.12±3.87 0.549 0.331
dSCV 10.91±3.27 9.53±2.53 0.081 0.005 *
dDCV 12.40±3.73 12.94±4.41 0.249 0.440
nSCV 10.80±3.32 9.54±3.36 0.549 0.028 *
nDCV 13.06±5.49 13.51±5.49 0.929 0.630
Note: * indicates 0.001 < P < 0.05 compared with the control group. ** 
indicates P < 0.001 compared with the control group.
3.4 Comparison of Blood Pressure Circadian 
Rhythm between Diabetic Group and Control 
Group
There was no significant difference between the two 
groups (P>0.05). Comparison of blood pressure circadi-
an rhythm between diabetic group and control group is 
shown in Table 5.
Table 5. Comparison of blood pressure circadian rhythm 
between diabetic group and control group
Blood pressure circadi-
an rhythm
Diabetes 
group n=59
Control 
group n=84 χ
2 P
Dipper 9 14
0.051 0.821
Non dipper 50 70
3.5 Comparison of Cognitive Function between 
Diabetic Group and Control group
There was a statistically significant difference in cognitive 
function between the two groups (0.001 < P < 0.05). Com-
parison of cognitive function between diabetic group and 
control group is shown in Table 6.
Table 6. Comparison of cognitive function between dia-
betic group and control group
Cognitive function status Diabetes group n=59
Control group 
n=84 χ
2 P
MCI 43 43
0.010 0.007 *
normal cognitive state 16 41
Note: * indicates 0.001 < P < 0.05 compared with the control group.
4. Discussion
The autonomic function of diabetic patients is abnormal. 
The function of sympathetic nerve and vagus nerve in 
diabetic patients is disordered. The nocturnal sympathetic 
excitability was relatively high and the proportion of dip-
per was decreased. This study found that the proportion 
of dipper was significantly lower than that of the normal 
population, which was consistent with its mechanism. 
Insulin, as a vascular factor, can promote atherosclero-
sis [14]. It can promote the hypertrophy and proliferation 
of arterial smooth muscle cells through insulin receptor 
or insulin-like growth factor, and lead to the increase of 
blood pressure. Insulin increases the activity of the sym-
pathetic nervous system [15]. Insulin enters the blood-brain 
barrier, binds to insulin receptors in the paraventricular 
nucleus and the arcuate nucleus around the ventricle, and 
sends excitatory signals to the sympathetic nucleus and 
inhibitory signals to the vagus nerve. Therefore, patients 
with diabetes mellitus and hypertension are more likely 
to have increased peripheral vascular resistance and ath-
erosclerosis than patients with simple hypertension. The 
study found that the hypertension group with diabetes was 
higher in 24hSBP, 24hPP, dSBP, dPP, nSBP and nPP than 
the simple hypertension group, which was consistent with 
the above theory. In this study, 24hSSD, dSSD, nSSD, 
24hSCV, dSCV and nSCV were also increased in the hy-
pertension group with diabetes mellitus compared with the 
simple hypertension group. 24hSCV, dSCV and nSCV are 
independent of the mean value of mean blood pressure. 
This suggests that diabetes may lead to increased variabil-
ity in blood pressure.
MCI (mild cognitive impairment) is a transitional state 
characterized by mild impairment of cognitive function 
between dementia and normal aging. Its daily living abil-
ity is retained and the overall cognitive function is intact. 
Kanemaru et al. [16] 's 24h dynamic blood pressure study 
showed that short-term variability of daytime blood pres-
sure and increased nocturnal systolic pressure were close-
ly related to cognitive impairment. The results showed 
that increased blood pressure variability was negatively 
associated with various cognitive function tests and was 
associated with a higher risk of stroke. This association 
was independent of a variety of other cardiovascular risk 
factors, particularly blood pressure levels. Many recent 
clinical and experimental evidences suggest that diabetes 
may be a risk factor for MCI. In addition to regulating 
glucose metabolism, insulin also plays a role in promoting 
the neural development of embryos, promoting the forma-
tion of synapses of nerve cells, increasing cell body area 
and promoting the synthesis of various proteins. In diabet-
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ics, the weakening of these effects of insulin is bound to 
lead to impaired cognitive function in the brain. Diabetes 
is a disease with insulin resistance as the core, which can 
lead to hyperinsulinemia. The study found that elderly 
diabetic patients with poor glycemic control performed 
worse in learning, reasoning and complex psychomotor 
functions than elderly type 2 diabetic patients with better 
glycemic control. At the same time, if severe hypoglyce-
mia occurs frequently, it will also damage the higher cor-
tex function, leading to the loss of sense of direction and 
consciousness and the impairment of cognitive function. 
Roberts RO et al. [17] found that the course of diabetes, age 
of onset, blood glucose control, and presence or absence 
of complications all increase the risk of MCI. Our study 
also found that the cognitive function of the hypertension 
group with diabetes was significantly different from that 
of the simple hypertension group. This can also reflect the 
impairment of cognitive function in diabetes.
5. Conclusion
The results suggest that blood pressure variability increas-
es in elderly patients with hypertension and diabetes and 
is associated with cognitive decline. Therefore, diabetic 
patients need to control blood glucose. The treatment of 
high blood pressure not only reduce the average blood 
pressure, but also should be able to smooth lowering 
blood pressure and blood pressure variability, in order to 
better prevent target organs damage and protect the cogni-
tive function.
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